Back to News
Market Impact: 0.15
Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Johnson & Johnson announced first real-world data for its VARIPULSE Pro Platform and 12-month outcomes for its OMNYPULSE Platform, both in atrial fibrillation treatment. The provided text contains no outcome figures or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
JNJ0.60
More News
- AI stocks tumble as the defensives rise. What it says about this uneasy market
- Asia stocks fall as AI rout batters S.Korea; Japan spooked by strong CPI
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Why is SK Hynix stock sliding today?
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Gold Holds Near Three-Month Low as AI Jitters Fuel Volatility